Insulin Degludec and Symptomatic Nocturnal Hypoglycaemia
Status:
Completed
Trial end date:
2019-02-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether insulin degludec compared to insulin
glargine can reduce the risk of symptomatic nocturnal hypoglycaemia in subjects with the
greatest potential benefit from optimised insulin treatment, which are patients with type 1
diabetes and high risk of nocturnal severe hypoglycaemia.
Phase:
Phase 4
Details
Lead Sponsor:
Nordsjaellands Hospital
Collaborators:
Aarhus University Hospital Copenhagen University Hospital, Denmark Hvidovre University Hospital Odense University Hospital Steno Diabetes Center Steno Diabetes Center Copenhagen Sydvestjysk Hospital Zealand University Hospital